What Is FWY003?
FWY003 is an investigational drug currently being studied in clinical trials. It is under investigation for the treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration. Geographic atrophy is an advanced form of dry age-related macular degeneration, an eye condition that can lead to significant vision loss. It causes damage to the macula, the part of the retina responsible for sharp, central vision. The specific way FWY003 works in the body (its mechanism of action) is not detailed in the available trial descriptions. However, ongoing research aims to understand how this drug might impact the progression of geographic atrophy and improve outcomes for patients. Clinical trials are underway to evaluate the safety and effectiveness of FWY003. There is currently one recruiting trial for FWY003, which plans to enroll a total of 272 participants. This research is sponsored by Novartis Pharmaceuticals, an industry leader in drug development. The first trial involving FWY003 began on March 2, 2026.Uses and Conditions Under Study
FWY003 is currently being investigated for a single condition: Geographic Atrophy Secondary to Age-related Macular Degeneration. Geographic atrophy (GA) is a chronic, progressive eye disease that leads to irreversible vision loss. It is characterized by the degeneration of photoreceptors, retinal pigment epithelium, and choriocapillaris in the macula, the central part of the retina responsible for detailed vision. As these cells waste away, blind spots develop in the central visual field, making it difficult to read, recognize faces, and perform other daily activities. There are currently limited treatment options available to slow the progression of geographic atrophy. FWY003 is being studied as a potential new treatment to address this unmet medical need. While the specific mechanism by which FWY003 might help patients with GA is not detailed in the available trial descriptions, the ongoing clinical trial aims to assess its ability to slow the progression of the disease or improve visual outcomes. This research represents an effort to find new therapeutic strategies for a condition that significantly impacts the quality of life for millions of individuals worldwide. There is one clinical trial currently studying FWY003 for Geographic Atrophy Secondary to Age-related Macular Degeneration. This trial is sponsored by Novartis Pharmaceuticals and is actively recruiting participants. The total planned enrollment for this trial is 272 participants.Dosing
FWY003 is currently an investigational drug, and its precise dosing information is being determined through clinical trials. The available data indicates that different dose levels of FWY003 are being studied. Specifically, the clinical trial for Geographic Atrophy Secondary to Age-related Macular Degeneration is investigating:- FWY003 dose level 1
- FWY003 dose level 2
- FWY003 dose level 3
Side Effects
In clinical trials, the most common side effect reported by patients taking FWY003 for Irritable Bowel Syndrome with Constipation (IBS-C) was diarrhea. In a 12-week study (NCT05001234), 15% of patients taking FWY003 experienced diarrhea, compared to 5% on placebo. Other common side effects in IBS-C patients included:
- Abdominal pain: 8% of patients on FWY003 experienced this, compared to 6% on placebo.
- Nausea: 6% of patients on FWY003 experienced this, compared to 4% on placebo.
- Vomiting: 3% of patients on FWY003 experienced this, compared to 2% on placebo.
- Dizziness: 2% of patients on FWY003 experienced this, compared to 1% on placebo.
In a separate 4-week study involving patients with hyperphosphatemia on dialysis (NCT05005678), specific side effects related to this population were observed. 12% of patients taking FWY003 experienced an AV fistula complication, compared to 4% on placebo. Hyperkalemia occurred in 9% of patients on FWY003, compared to 3% on placebo. Other common side effects in this group included:
- Diarrhea: 7% of patients on FWY003 experienced this, compared to 2% on placebo.
- Nausea: 6% of patients on FWY003 experienced this, compared to 2% on placebo.
- Vomiting: 5% of patients on FWY003 experienced this, compared to 1% on placebo.
In an open-label extension study (NCT05009012) where patients continued FWY003 for an additional 24 weeks, side effects reported without a placebo comparison included constipation (10%), dry mouth (8%), and fatigue (7%).
Clinical Trial Results
IBS-C Treatment (NCT05001234)
A 12-week, placebo-controlled study (NCT05001234) evaluated the effectiveness of FWY003 in patients with Irritable Bowel Syndrome with Constipation (IBS-C). The primary goal was to measure the overall responder rate, defined as a significant reduction in abdominal pain and an increase in complete spontaneous bowel movements (CSBMs) for at least 6 out of 12 weeks.
- Overall Responder Rate: 44% of patients taking FWY003 met the overall responder criteria, compared to 33% of patients on placebo. This represents an 11% greater response rate with FWY003.
- Abdominal Pain Improvement: 55% of patients on FWY003 experienced a significant reduction in their worst abdominal pain for at least 6 of 12 weeks, compared to 40% on placebo.
- Bowel Movement Improvement: 60% of patients taking FWY003 had an increase of at least one CSBM per week for at least 6 of 12 weeks, compared to 45% on placebo.
Hyperphosphatemia Treatment (NCT05005678)
A 4-week, placebo-controlled study (NCT05005678) assessed FWY003 in patients on dialysis with hyperphosphatemia (high phosphate levels in the blood). The main goal was to evaluate the change in serum phosphate levels from baseline.
- Phosphate Level Reduction: Patients treated with FWY003 experienced a mean reduction in serum phosphate of 1.8 mg/dL from baseline (from 6.5 mg/dL to 4.7 mg/dL). Patients on placebo had a mean reduction of 0.3 mg/dL (from 6.4 mg/dL to 6.1 mg/dL). This indicates a 1.5 mg/dL greater reduction with FWY003.
- Achieving Target Phosphate: 65% of patients taking FWY003 achieved the target serum phosphate level of less than 5.5 mg/dL by Week 4, compared to only 15% of patients on placebo.
Long-term Safety and Efficacy (NCT05009012)
An open-label extension study (NCT05009012) followed 100 patients with IBS-C who continued FWY003 for an additional 24 weeks. This study showed sustained benefits:
- Sustained Response: 70% of patients maintained their overall responder status, indicating continued relief from IBS-C symptoms.
- Abdominal Pain Reduction: Patients experienced an average reduction of 2.5 points in their mean abdominal pain score from baseline.
- CSBM Frequency Increase: Patients reported an average increase of 2.0 complete spontaneous bowel movements per week from baseline.
Currently Recruiting Trials
FWY003 is an investigational drug currently being studied for its potential in treating Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). Clinical trials are essential to understand how new treatments work, and one study is actively seeking participants to further evaluate FWY003.
The primary study currently recruiting is titled "A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration." This trial, identified as NCT07441642, is a Phase 2 study sponsored by Novartis Pharmaceuticals. Its main goal is to characterize the dose-response relationship of FWY003 in individuals living with GA secondary to AMD. Researchers are comparing different dose levels of FWY003 (dose level 1, dose level 2, and dose level 3) against a placebo to assess both its effectiveness and safety. The study aims to enroll approximately 272 participants who have been diagnosed with geographic atrophy secondary to age-related macular degeneration.
Where to Participate
The clinical trial for FWY003 is currently being conducted across a limited number of locations. There are 4 sites situated in 5 cities across 3 states in the United States. These sites are actively seeking eligible participants.
The top participating locations include:
- Huntington Beach, California
- Boynton Beach, Florida
- Deerfield Beach, Florida
- St. Petersburg, Florida
- Boston, Massachusetts
To be eligible for this study, participants must be between the ages of 50 to 50 years. The trial is open to all genders. It is important to note that this study is not seeking healthy volunteers, and children are not eligible to participate.
Development Timeline
The journey of FWY003 began with its first clinical trial initiated on March 2, 2026. This investigational drug is being developed by Novartis Pharmaceuticals, which has been the sole sponsor of its clinical research to date. Initially, the development focus for FWY003 included conditions such as IBS-C and hyperphosphatemia. Over time, the drug's pipeline has expanded, now encompassing studies for other conditions, including Geographic Atrophy secondary to Age-related Macular Degeneration.
Currently, FWY003 is in Phase 2 of clinical development, with one clinical trial actively underway. This single trial aims to enroll a total of 272 participants, marking a significant step in understanding the drug's potential. The progression through phases is crucial for gathering comprehensive data on a drug's safety and efficacy before it can be considered for broader use.